Head to Head Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) & Synaptogenix (NASDAQ:TAOX)

Synaptogenix (NASDAQ:TAOX) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Risk and Volatility

Synaptogenix has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Synaptogenix and ASLAN Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
ASLAN Pharmaceuticals	0	0	0	0	0.00

Profitability

This table compares Synaptogenix and ASLAN Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Institutional & Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Synaptogenix and ASLAN Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$687,835.00	39.76	-$28.74 million	($13.28)	-0.28
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03

Synaptogenix has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Synaptogenix is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Synaptogenix beats ASLAN Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.